Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome program
read at Endpoints ↗DealPositive
Encoded Therapeutics announced closing a Series F financing round that brought in $275 million.
The round was led by GV with participation from an undisclosed healthcare investor. The new capital will support development of the company’s precision genetic medicine targeting Dravet syndrome.
The funding highlights investor confidence in Encoded’s approach to treating the rare epileptic disorder.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Encoded closes $275M Series F for Dravet syndrome drug”
read at Endpoints ↗81 words · retrieved Sep 9
comments(0)
5-min edit window · permanent after that